An experimental pill has achieved the complete remission of cancer in 18 near-terminal patients with aggressive tumors that did not respond to treatments. Hematologist Pau Montesinos, coordinator of the Spanish Group of Acute Myeloid Leukemia, believes that the new information is “fairly hopeful,” but she emphasizes the caveats: revumenib still must be tested on hundreds of people to confirm its safety and effectiveness. As Ghayas Issa and his colleague Eytan Stein observe, menin inhibitors “will definitely be part of a treatment for these leukemias